Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02791035

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02791035
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02791035. Allocation not applicable; no masking; primary purpose other. Start 2016-06 (registry gives no type); primary completion 2017-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Oral administration of Ipragliflozin
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Severance Hospital (class: other)
Collaborator
Samsung Medical Center (class: other)
Collaborator
Kyung Hee University Hospital at Gangdong (class: other)
Collaborator
Astellas Pharma Korea, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02791035
Content hash
b6835c80b77080267659b0f9f996245bdf963676683086419f4d77c5aaae3923